Table 3.

Dropout Rates in the Amisulpride Studies

	Amisulpride		Haloperidola		All
	n	%	n	%	N	%
Pooled studies
Completed	590	66.6	253	56.9	843	63.3
Lost to follow-up	18	2.0	10	2.2	29	2.2
Inefficacy	83	9.4	52	11.7	135	10.1
Adverse event	50	5.6	65	14.6	115	8.6
Uncooperative	112	12.6	48	10.8	160	12.0
Recovery	4	0.5	2	0.4	6	0.5
Other	29	3.3	15	3.4	44	3.3
Total	886	100.0	445	100.0	1332	100.0
Wetzel et al9
Completed	51	71.8	37	59.7	88	66.2
Lost to follow-up	0	0.0	0	0.0	0	0.0
Inefficacy	5	7.0	8	12.9	13	9.8
Adverse event	5	7.0	11	17.7	16	12.0
Uncooperative	6	8.5	4	6.5	10	7.5
Recovery	2	2.8	1	1.6	3	2.3
Other	2	2.8	1	1.6	3	2.3
Total	71	100.0	62	100.0	133	100.0
Puech et al8
Completed	149	76.8	43	67.2	192	74.4
Lost to follow-up	3	1.5	0	0.0	3	1.2
Inefficacy	20	10.3	4	6.3	24	9.3
Adverse event	8	4.1	10	15.6	18	7.0
Uncooperative	8	4.1	7	10.9	15	5.8
Recovery	1	0.5	0	0.0	1	0.4
Other	5	2.6	0	0.0	5	1.9
Total	194	100.0	64	100.0	258	100.0
Möller et al7
Completed	70	73.7	57	59.4	127	66.5
Lost to follow-up	1	1.1	2	2.1	3	1.6
Inefficacy	11	11.6	11	11.5	22	11.5
Adverse event	3	3.2	10	10.4	13	6.8
Uncooperative	8	8.4	11	11.5	19	9.9
Recovery	0	0.0	0	0.0	0	0.0
Other	2	2.1	5	5.2	7	3.7
Total	95	100.0	96	100.0	191	100.0
Colonna et al5
Completed	203	55.2	57	48.3	260	53.4
Lost to follow-up	10	2.7	5	4.2	16	3.3
Inefficacy	33	9.0	20	16.9	53	10.9
Adverse event	30	8.2	12	10.2	42	8.6
Uncooperative	77	20.9	17	14.4	94	19.3
Recovery	1	0.3	0	0.0	1	0.2
Other	14	3.8	7	5.9	21	4.3
Total	368	100.0	118	100.0	487	100.0
Carrière et al6
Completed	72	74.2	59	56.2	131	64.9
Lost to follow-up	2	2.1	3	2.9	5	2.5
Inefficacy	6	6.2	9	8.6	15	7.4
Adverse event	4	4.1	22	21.0	26	12.9
Uncooperative	8	8.2	9	8.6	17	8.4
Recovery	0	0.0	1	1.0	1	0.5
Other	5	5.2	2	1.9	7	3.5
Total	97	100.0	105	100.0	202	100.0

Note: n, number of patients.

^aIn Wetzel et al,⁹ the comparator was flupenthixol.